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Abstract
Background:  Increase of EGFR  gene copy number consequent to gene amplification and/or
polysomy of chromosome 7 has been significantly associated with better clinical outcome in Non
Small Cell Lung Cancer (NSCLC) patients treated with Tyrosin-Kinase Inhibitors (TKIs).
The primary method to detect EGFR copy number is FISH (Fluorescence in Situ Hybridization), that
in lung cancer requires a precise standardization due to the presence of intratumor heterogeneity
and high frequency of chromosome 7 polysomy.
Recommendations and interpretative guidelines to discriminate NSCLC patients into FISH positive
(gene amplification and high chromosome 7 polysomy) and FISH negative have been proposed by
the University of Colorado Cancer Center (UCCC). However, in a subset of cases the distinction
between EGFR amplification and chromosome 7 polysomy can be controversial because of a
complex pattern of multiple EGFR and centromere signals.
Methods: In order to distinguish more accurately these two genetic events, 20 NSCLC FISH
positive patients, showing a controversial pattern of EGFR and centromere specific signals, were
further evaluated for the status of 7q31 distal region.
Results: A discrepancy between FISH results obtained with UCCC scoring system and 7q31
control was evidenced in 2 patients (10%).
Conclusion: Our data strengthen the usefulness of 7q31 region evaluation to discriminate EGFR
amplification from chromosome 7 polysomy in controversial EGFR FISH positive cases. Since it has
been reported a possible different contribution of amplification and polysomy to TKIs susceptibility
in NSCLC, the clear distinction between these two genetic events may be important to identify a
subset of patients more responsive to the therapy.
Background
The development and clinical application of Tyrosine
Kinase Inhibitors (TKIs) targeting the Epidermal Growth
Factor Receptor (EGFR), such as erlotinib and gefitinib,
provide important insights for the treatment of non small
cell lung cancer (NSCLC). However, patients derive differ-
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ent degrees of benefit from treatment with EGFR TKIs [1-
3]. Several molecular studies showed that sensitivity to
EGFR TKIs correlated very strongly with a class of somatic
activating mutations of EGFR kinase domain that target
mainly two exons (19 and 21), indicating that patients
harbouring  EGFR  mutations have a higher partial and
complete response rate to EGFR TKIs therapy than those
without mutations [4-6]. Overall, the incidence of EGFR
mutations in NSCLC among clinical responders to gefit-
inib or erlotinib is 77%, but this is not always associated
with prolonged survival [7-11]. However, approximately
10-20% of patients who show a partial response to EGFR
TKIs have not detectable EGFR  mutations, suggesting
other molecular mechanisms are involved in TKIs
response [9].
Although a conclusive picture has yet to emerge, an asso-
ciation between increased EGFR  gene copy number,
detected by Fluorescence in Situ Hybridization (FISH),
and sensitivity to TKIs therapy was observed. Cappuzzo et
al. [12] reported that FISH positive patients showed a bet-
ter response and an increased survival in respect to FISH
negative patients (36% vs 3% and 18 months vs 7 months,
respectively). Different studies [13-18] demonstrated a
significant association between high EGFR copy number
and response to gefitinib, time to progression and sur-
vival. In addition, it was shown that patients negative for
at least two tests among mutation, FISH and immunohys-
tochemistry had no benefit from TKI therapy [19].
According to the Molecular Assays in NSCLC Working
Group, FISH represents the gold standard method to
establish gene numerical status combining the gene spe-
cific probe and the control centromeric probe [20]. FISH
allows to detect the real amount of gene copies in relation
to the chromosome number and discriminate between
gene amplification from high gene copy number due to
polysomy. Normally amplification is expressed as gene
copy number/chromosome control number ratio of > 2.
In NSCLC high EGFR gene copy number results mostly
from chromosome 7 polysomy while less often from gene
amplification. In the first case, the high number of chro-
mosome 7 centromeres lowers the gene/chromosome
ratio value to less than 2, masking possible amplification
events. Moreover, EGFR gene is located at the band 7p12,
very close to the centromere; as a consequence, in a subset
of tumors amplification involves EGFR gene and centro-
meric sequences too, originating a complex pattern of
multiple red and green signals difficult to classify as
amplification or high polysomy.
Recently, a FISH scoring system and guidelines for EGFR
FISH assay in NSCLC patients have been proposed by the
University of Colorado Cancer Center (UCCC). This sys-
tem stratifies results into six groups by number of copies
of the EGFR gene, including disomy, low trisomy, high tri-
somy, low polysomy, high polysomy and gene amplifica-
tion. High polysomy and gene amplification are
considered FISH positive, the cut-off being assumed on a
retrospective study performed in advanced NSCLC
patients treated with gefitinib [21]. Although the scoring
criteria of UCCC for stratification of NSCLC patients with
EGFR  FISH assay effectively copes with complexity of
EGFR gene amplification mechanisms, it doesn't always
allow to discriminate between real gene amplification and
high level polysomy, particularly when almost the same
number of centromere 7 and EGFR gene signals is present.
The aim of the study was to improve the discrimination
between amplification and high level polysomy in those
controversial cases that are characterized by multiple cop-
ies of both EGFR gene and centrome. To this purpose, we
have introduced the FISH evaluation of a further chromo-
some 7 region (7q31), sufficiently far from EGFR locus
(7p12), in 20 selected FISH positive patients showing a
complex pattern of EGFR and centromere signals.
Materials and methods
Patients and samples
The study was conducted on 20 NSCLC patients selected
over 90 (median age: 69; range 44-87 years) with cytolog-
ically or hystologically confirmed NSCLC in advanced
stage (III-IV), according to WHO criteria: 18 adenocarci-
noma, 1 mucoepidermoid carcinoma and 1 squamous
cell carcinoma. The majority were females (14/20; 70%)
and never smokers (16/20; 80%). Eleven patients (55%)
had a history of metastasis. Mutations of EGFR gene were
present in 18/20 patients (90%) who, consequently,
received therapy with erlotinib. Ten patient had exon 19
deletion, 7 had mutation of exon 21 (6 cases with substi-
tution L2573 T>G and 1 case with substitution L2558
T>C) and 1 had exon 20 deletion.
All patients had been found EGFR  FISH positive for
amplification or high level polisomy in a preliminary
analysis. They were selected for this study because of a
high number of both EGFR and centromere signals in the
absence of peculiar traits of gene amplification, such as
EGFR/CEP 7 ratio >2, or the presence of large or small
clusters of signals. Such a picture is particularly difficult to
interpret because it might reflect either an amplification
involving EGFR gene together with centromeric sequences
or, alternatively, a polysomy of chromosome 7.
The preliminary FISH analysis was carried out using LSI
EGFR/CEP 7 (Vysis-Abbott). According to UCCC criteria,
high level polysomy was defined as the presence ≥ 4 EGFR
copies in > 40% of cells, and gene amplification as: a)
EGFR/centromere 7 ratio ≥ 2 b) presence of small geneDiagnostic Pathology 2009, 4:36 http://www.diagnosticpathology.org/content/4/1/36
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clusters (4-10 copies) in ≥ 10% of the tumor cells c) larger
and brighter EGFR signals than expected in >10% of the
tumor cells d) ≥ 15 copies of the EGFR signals in ≥ 10% of
the tumor cells.
The evaluation of 7q31 region was performed by FISH on
paraffin embedded specimens derived from 18 primary
tumors and 2 secondary lesions (lymph node and bone).
These specimens included 2 tissue sections from surgical
lobectomy, 6 fine needle aspiration/core biopsies
(FNAB), 3 endoscopic bronchial biopsies, 3 bronchial
washings and 6 pleural effusions.
In 10 cases the median number of EGFR gene (EGFR gene/
nuclei ratio) and the median number of chromosome 7
centromere (centromere 7/nuclei ratio) were very similar
with a Δ < 1 unit. In the other 10 cases the median number
of EGFR  gene was higher than the median number of
chromosome 7 centromere that, nevertheless, ranged
from 6 to 23 copies.
7q31 FISH Analysis
FISH analysis was performed using standard methods. In
brief, 4-6 μm paraffin embedded tissue sections were
deparaffinized and subsequently enzymatically digested
with a commercial kit (Paraffin pretreatment reagent kit,
Vysis-Abbott Molecular, Downers Grove, IL, USA). Sam-
ple DNA was denaturated at 75°C for 5 minutes. Spec-
trum-Orange-labeled LSI D7S522 probe, that hybridises
to band 7q31, was used together with Spectrum-Green-
labelled centromere 7 reference probe (LSI D7S522/CEP
7, Vysis-Abbott). The probe mix (10 μl), previously dena-
turated for 5' at 75°C, was applied on each slide. The
slides, covered with a glass coverslip, were incubated for 5'
at 79° for codenaturation and placed in a humidified
chamber at 37°C overnight to allow hybridisation to
occur. After post-hybridization washes, carried out
according to manifacturer's protocols, tissue sections were
counterstained with DAPI I (Vysis-Abbott) and examined
with a fluorescence microscope (Olympus, Tokyo, Japan).
An average of 40 non-overlapping nuclei with intact mor-
phology were analysed using H&E-stained sections as
hysto-topographic reference. Copy number of 7q31 spe-
cific signals was estimated for each tumor sample and the
median number of 7q31 band signals (7q31 number/
nuclei) was calculated for each patient. Particular atten-
tion was focused on those nuclei exhibiting high number
of chromosome 7 centromeres. If the copy number of
7q31 region was not increased similarly to chromosome 7
centromere, polysomy could be excluded; conversely,
increased 7q31 signals paralleling the increased centro-
mere signals was considered as a signature of polysomy
(Fig. 1).
Results
According to UCCC scoring system, 13 out of 20 patients
(65%) showed high level polysomy. Seven patients (35%)
were classified as amplified cases, because of the presence
of EGFR/CEP7 ratio >2 (cases n° 4 and 20), tight gene
clusters and larger and brighter EGFR signals in > 10% of
cells (n° 5 and 19) and of >15 EGFR signals in ≥ 10% of
cells (n° 2, 7 and 13).
Using 7q31 band FISH evaluation, almost the same mean
number of 7q31 band and chromosome 7 centromeres
was observed in 10 cases (n° 3, 5, 6, 9, 14, 15, 16, 17, 18,
19), confirming a polysomic status. In cases n° 5 and 19,
however, a cell population with amplification was co-
present. In 4 cases (cases n° 4, 7, 10, 13) 7q31 mean
number was lower than centromere mean number as
expected in case of gene amplification. Patients n° 2 and
11 who had very similar value for EGFR gene and 7q31
band, even higher than centromere number, were consid-
ered polysomic. Patients n° 1, 8, 12, because of their rela-
tively low EGFR  copy number, were supposed to be
polysomic even if 7q31 mean number was lower than
centromere mean number. In these cases the presence of
complex chromosomal rearrangements, resulting in chro-
mosome 7 long arm losses and short arm gains, was more
conceivable.
The results obtained applying UCCC criteria alone and
UCCC criteria together with 7q31 FISH control were in
agreement in 18/20 cases (90%). Case n° 2, classified as
amplified having 10% of cells with >15 EGFR copies, had
to be defined polysomic because of the presence of about
EGFR/CEP7 co-amplification or Polisomy of chromosome 7? Figure 1
EGFR/CEP7 co-amplification or Polisomy of chromo-
some 7?. In case of polysomy, the copy number of 7q31 
region increases similarly to centromere signals. EGFR high 
copy number in the presence of an eusomic status of 7q31 
region is indicative of gene amplification.
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the same number of 7q31 band and EGFR gene. In case n°
10, according to UCCC protocol, the presence of nuclei
with EGFR gene high number (>15) confined just in 2,7%
of cells suggested chromosome 7 polysomy rather than
amplification. The eusomic status of 7q31 region (7q31/
nuclei ratio = 2.2), much lower than centromere mean
number, might be the consequence of chromosome 7
long arm deletion, resulting in 7q31 loss.
However, the presence of EGFR increased copy number
with a percentage of cells harbouring >15 EGFR signals
(even <10% of neoplastic population), together with a
high number of chromosome 7 centromeres and a very
low number of 7q31 region, suggested a gene amplifica-
tion rather than chromosome 7 polysomy associated with
deletion 7q31 (Fig. 2).
Results obtained with UCCC criteria alone and UCCC cri-
teria with 7q31 FISH control are compared in Table 1.
Discussion
The development of small molecule inhibitors of EGFR
resulted in new therapeutics options for patients with
advanced NSCLC. Clinical trials provide sufficient evi-
dence that identification of molecular markers for predict-
ing the effects of TKIs may become an integral part of the
future standard of care for patients with NSCLC [22-27].
As a consequence, standardized assay procedures must be
developed.
Although the significance is still controversial [28-30],
EGFR  copy number may be predictive of response to
EGFR TKIs therapy and, presently, FISH is the gold stand-
ard method to detect EGFR gene numerical status. Nor-
mally, the gene specific probe is used coupled with a
centromeric probe as control to assist in distinguishing
gene amplification from chromosomal polysomy.
Increased gene copy number, in association with an
increase in the number of the chromosome the gene maps
on, is interpreted as polysomy. However, FISH analysis in
NSCLC is complicated by multiple factors. Lung cancers
are frequently heterogeneous with significant variability
of EGFR copy number within the same tumor. Moreover,
in NSCLC high EGFR  gene copy number results more
often from chromosome 7 polysomy rather than gene
amplification. This depends on the high level of chromo-
somal instability, as demonstrated by the extremely com-
plex karyotypes. The modal chromosome numbers
usually cluster in the near-triploid to near-tetraploid range
and the most frequent numerical alteration is polysomy 7
or 7p, with the number of 7/7p exceeding the number of
copies expected based on the ploidy of the tumor. Even
among the structural rearrangements, the most frequently
affected band is 7p11-12, where EGFR gene maps [31-33].
Furthermore, EGFR gene is located at the band 7p12 very
close to centromere and EGFR amplicon may include cen-
tromeric sequences too, originating a coamplification-
type gene amplification, with a complex pattern of sig-
nals. Finally, polysomy may coexist with gene amplifica-
tion, giving rise to a high number of both centromere and
EGFR signals.
A useful FISH scoring system for EGFR FISH evaluation in
NSCLC patients has been introduced by the University of
Colorado Cancer Center (UCCC) [21]. This system strati-
fies results into six groups (disomy, low trisomy, high tri-
somy, low polysomy, high polysomy and gene
amplification) according to the number of copies of the
EGFR  gene, chromosome 7 centromere and their fre-
quency in tumor cells of the sample. High polysomy and
gene amplification are considered FISH positive.
The guidelines suggested by the Molecular Assays in
NSCLC Working Group recommend a two color FISH
with centromeric probe as control and encourage the scor-
ing system described by the Colorado group to be used for
FISH assay interpretation. Nevertheless authors invite
other investigators to propose algorithms for EGFR FISH
evaluation [20].
In our study, we introduced a further FISH control, analys-
ing chromosome 7 distal region (7q31) in a series of 20
FISH analysis of 7q31 region Figure 2
FISH analysis of 7q31 region. Case n° 10: a) FISH in bron-
chial biopsy section showing gain of both EGFR gene and 
chromosome 7 centromere; b) the patient is classified as 
amplified on the basis of eusomic status of 7q31 region. Case 
n° 2: c) FISH in pleural effusion sample with EGFR and cen-
tromere balanced aneusomy; d) increased copy number of 
7q31 region is a signature of polysomy.Diagnostic Pathology 2009, 4:36 http://www.diagnosticpathology.org/content/4/1/36
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Table 1: FISH results according to UCCC criteria and 7q31 control
Case
N°
EGFR/
CEP7 
Ratio
EGFR/
NUCLEI 
Ratio 
(Range)
CEP7/
NUCLEI 
Ratio
(Range)
% of cells 
with >4 
EGFR 
copies
NOTES RESULTS 
(UCCC 
criteria)
7q31/
NUCLEI 
Ratio 
(Range)
CEP7/
NUCLEI 
Ratio 
(Range)
RESULTS 
(7q31 
control)
1 1.13 5.35 (3-8) 4.7 (2-8) 85% P 2.02 (1-4) 4 (2-8) P
2 1.50 8.4 (4-17) 5.55 (2-10) 100% 10% of cells 
with >15 
EGFR copies
A 8.58 (4-14) 7.2 (2-13) P
3 1.09 4.48 (3-9) 4.1 (2-9) 89% P 3.97 (2-5) 4.8 (2-7) P
4 2.80 12.42 (5-23) 4 (2-7) 100% EGFR/CEP7 
Ratio >2
A 2(2) 5.3 (4-8) A
5 1.50 7.4 (3-16) 4.9 (2-8) 100% 22,5% of cells 
with tight 
gene clusters
A 4.48 (2-9) 4 (2-7) A
6 1.45 6.2 (3-12) 4.2 (2-8) 84% P 4.44 (3-7) 4.72 (2-7) P
7 1.0 15.2 (10-40) 14.5 (8-35) 100% 80% of cells 
with >15 
EGFR copies
A 1.70 18 (12-45) A
8 1.16 5.58 (3-10) 4.78 (3-9) 97% P 2.37 (1-4) 5.2 (4-10) P
9 1.05 4.92 (2-11) 4.64 (2-9) 82% P 5.07 (2-9) 6.7 (2-11) P
10 1.69 8.52 (4-22) 5.04 (2-9) 97% 2.4% of cells 
with >15 
EGFR copies
P 2.2 (1-4) 5 (2-12) A
11 1.24 4.89 (2-10) 3.93 (2-8) 75% P 6.07 (3-12) 6 (2-10) P
12 1.32 7.96 (3-15) 6.01 (3-9) 97% 2,7% of cells 
with >15 
EGFR copies
P 3.2 (1-6) 6 (3-10) P
13 1.25 10.5 (4-26) 8.36 (4-23) 100% 16% of cells 
with >15 
EGFR copies
A 2.6 (2-5) 7.7 (4-18) A
14 1.06 5.95 (2-13) 5.6 (2-12) 100% P 4.1 (2-5) 6.3 (2-11) P
15 1.18 4.39 (2-13) 3.72 (1-13) 72% P 3.36(2-5) 3.9 (2-10) P
16 1.22 4.64 (2-9) 3.78 (2-6) 71% P 2.35 (1-3) 4.2 (2-7) P
17 1.70 3.9 (1-8) 2.2 (1-5) 55% P 2.24 (1-4) 3 (2-6) P
18 1.10 4.9 (2-8) 4.4 (2-7) 90% P 6.02 (4-9) 7.4 (2-10) P
19 1.40 6.4 (3-23) 4.7 (1-10) 93% Tight gene 
clusters in 
11,5% of cells
A 4.15 (2-7) 5.6 (2-10) A
20 2.90 8.8 (2-13) 3.1 (2-6) 88% EGFR/CEP7 
Ratio >2
A 1.6 (1-3) 2.1 (2-5) A
A = Amplification; P = PolysomyDiagnostic Pathology 2009, 4:36 http://www.diagnosticpathology.org/content/4/1/36
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FISH positive patients with advanced NSCLC and a com-
plex pattern of signals. Fair concordance was seen in 18/
20 (90%) cases. However in 2 cases (10%) we found dis-
crepancy between FISH results obtained with UCCC scor-
ing system and 7q31 FISH control. According to UCCC
criteria, patient n° 2, because of the presence of 10% of
cells with >15 EGFR gene copies, was considered ampli-
fied. On the contrary, FISH evaluation of 7q31 region
revealed almost the same number of both 7q31 and cen-
tromere signals (8,4 vs. 8,58), showing that the EGFR gene
increased copy number is consequent to chromosome 7
polysomy. Patient n° 10, having <10% of cells with >15
EGFR gene copies, was classified as polysomic. However,
the eusomic status of 7q31 band suggested the presence of
EGFR gene amplification. Our results show that in contro-
versial cases, characterized by multiple EGFR and centro-
mere specific signals, 7q31 FISH detection increases
accuracy in discriminate EGFR amplification from chro-
mosome 7 polysomy.
From the molecular point of view, amplification and
polysomy are different genetic events. Amplification is an
alteration by which a cell acquires multiple copies of a
DNA sequence, the size ranging from a few hundred kilo-
bases to megabases and is one of the mechanisms by
which protooncogenes may be activated in tumor cells. In
that case chromosomes may display homogeneously
staining regions or small acentric circular autonomously
replicating double minutes. Polisomy, reflecting genetic
instability, may arise from mitotic non-disjunction fol-
lowed by secondary endoreduplication events, and dereg-
ulate global gene transcription in cancer cells.
In contrast to breast cancer, where HER2 amplification,
but not chromosome 17 polysomy seems to confer sensi-
tivity to monoclonal antibody trastuzumab [34,35], it has
been reported that patients with NSCLC can derive a clin-
ical benefit from TKIs therapy when EGFR increased copy
number (ICN) is found, without distinction between
amplification and/or high level of chromosome 7p poli-
somy. However, recent in vitro and clinical studies,
focused on the relationship between mutations and ICN
of EGFR gene, have shown that mutations are preferen-
tially associated with amplification of the gene. The obser-
vation that four of six human NSCLC cell lines harbouring
EGFR  mutations were positive for EGFR  amplification,
whereas none of the ten cell lines negative for EGFR muta-
tions manifested EGFR amplification, supported a close
association between these two genetic alterations [36]. As
far as clinical studies, Nomura et al (2007) observed a
close relationship between three polymorphisms of EGFR
gene, activating mutations, and selective amplification of
the mutant allele, suggesting that just mutation promotes
and drives mechanisms of amplification [37]. Similar evi-
dence was reported in glioblastomas, where the variant
form of EGFR gene frequently demonstrates allele-specific
amplification [38,39]. Recent studies have reported that
EGFR mutations occur early during multistage pathogen-
esis of NSCLC and precede amplification, but not neces-
sarily high polysomy [37,40,41]. In addition, Morinaga et
al (2008) observed a specific association between muta-
tions and amplification, underlying that EGFR amplifica-
tion, but not high polysomy, correlates with mutations
[42].
As a consequence, a higher sensitivity and specificity of
the EGFR FISH assay can turn out in an improved identi-
fication of those subsets of patients who can benefit more
from TKI therapy.
We are currently investigating a wider cohort to character-
ize furtherly the relationship among ICN, mutations and
TKI response. Preliminary data, regarding 16 EGFR
mutated patients, indicate that the median overall sur-
vival is 16 months in presence of an EGFR amplification
vs  9.5 months in cases associated with 7p polysomy
(unpublished data).
In conclusion, as it is conceivable that amplification and
polysomy differently affects EGFR expression, activation,
and sensitivity to TKIs, we underlie the importance of dis-
criminating these two genetic events with accuracy.
Conclusion
Results from this study strengthen the applicability and
usefulness of the scoring criteria developed at UCCC for
the assessment of EGFR gene patterns, however the further
control of a different and distal region of chromosome 7,
specifically 7q31, adds more accuracy in interpreting con-
troversial FISH results, when multiple centromeric and
gene specific signals are present. Distinction between
EGFR gene amplification and high chromosome 7 polys-
omy is required, till the role of increased EGFR  copy
number in NSCLC patients in contributing to lung cancer
oncogenesis and susceptibility to TKIs will be definitely
established.
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